MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Thermo Fisher Scientific Retained Earnings 2011-2026 | TMO
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Thermo Fisher Scientific
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 59.2 B | 53.1 B | 47.4 B | 41.9 B | 35.4 B | 28.1 B | 22.1 B | 18.7 B | 15.9 B | 13.9 B | 12.1 B | 10.4 B | 8.75 B | 7.7 B | 6.72 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 59.2 B | 6.72 B | 25.4 B |
Quarterly Retained Earnings Thermo Fisher Scientific
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 57.4 B | 55.9 B | 54.4 B | 51.4 B | 49.9 B | 48.5 B | 45.9 B | 44.3 B | 43.1 B | 41.9 B | 40.5 B | - | 37.5 B | 35.4 B | 33.9 B | 32.1 B | 30.4 B | 28.1 B | 28.1 B | 28.1 B | 28.1 B | 22.1 B | 22.1 B | 22.1 B | 22.1 B | 18.7 B | 18.7 B | 18.7 B | 18.7 B | 15.9 B | 15.9 B | 15.9 B | 15.9 B | 13.9 B | 13.9 B | 13.9 B | 13.9 B | 12.1 B | 12.1 B | 12.1 B | 12.1 B | 10.4 B | 10.4 B | 10.4 B | 10.4 B | 8.75 B | 8.75 B | 8.75 B | 8.75 B | 7.7 B | 7.7 B | 7.7 B | 7.7 B | 6.72 B | 6.72 B | 6.72 B | 6.72 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 57.4 B | 6.72 B | 22.9 B |
Retained Earnings of other stocks in the Diagnostics research industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
-280 M | - | -17.87 % | $ 25.9 M |  Canada |
|
Centogene N.V.
CNTG
|
-62.9 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
348 M | $ 115.62 | 0.06 % | $ 35.1 B |  USA |
 |
Accelerate Diagnostics
AXDX
|
-607 M | - | -61.36 % | $ 2.46 M | USA |
 |
Chembio Diagnostics
CEMI
|
-154 M | - | 0.22 % | $ 16.8 M | USA |
 |
Co-Diagnostics
CODX
|
-80.4 M | $ 1.65 | -1.2 % | $ 2.19 M | USA |
 |
Aspira Women's Health
AWH
|
-544 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
-298 M | - | -13.05 % | $ 7.29 M | USA |
 |
Castle Biosciences
CSTL
|
-200 M | $ 24.98 | 2.13 % | $ 694 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-170 M | - | - | $ 9.42 M |  Israel |
 |
Enzo Biochem
ENZ
|
-294 M | - | -8.98 % | $ 14.8 K | USA |
 |
CareDx, Inc
CDNA
|
-735 M | $ 21.85 | 2.92 % | $ 1.16 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-84 M | - | - | $ 562 M |  Britain |
 |
DermTech
DMTK
|
-424 M | - | -11.32 % | $ 2.94 M | USA |
 |
Exact Sciences Corporation
EXAS
|
-4.71 B | - | - | $ 19.8 B | USA |
 |
Fulgent Genetics
FLGT
|
590 M | $ 15.6 | -4.35 % | $ 472 M | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-230 M | - | -20.0 % | $ 1.06 M | USA |
 |
Global Cord Blood Corporation
CO
|
2.89 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
-624 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-150 M | - | - | $ 7.1 B |  Australia |
 |
Illumina
ILMN
|
-1.24 B | $ 128.52 | 0.5 % | $ 20.4 B | USA |
 |
Genetron Holdings Limited
GTH
|
-4.94 B | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
1.39 B | $ 171.23 | 0.86 % | $ 8.49 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
440 M | - | - | $ 10.7 B | USA |
 |
Guardant Health
GH
|
-2.99 B | $ 88.5 | -0.46 % | $ 11.1 B | USA |
 |
Heska Corporation
HSKA
|
-169 M | - | - | $ 1.31 B | USA |
 |
Interpace Biosciences
IDXG
|
-211 M | $ 1.93 | -2.08 % | $ 8.54 M | USA |
 |
Lantheus Holdings
LNTH
|
680 M | $ 84.11 | -0.26 % | $ 5.68 B | USA |
 |
Medpace Holdings
MEDP
|
-460 M | $ 421.37 | 2.64 % | $ 12.2 B | USA |
 |
QIAGEN N.V.
QGEN
|
2.75 B | - | - | $ 10.6 B |  Niderland |
 |
Motus GI Holdings
MOTS
|
-154 M | - | -34.28 % | $ 263 K | Israel |
 |
Biomerica
BMRA
|
-53.2 M | $ 2.18 | 1.87 % | $ 5.01 M | USA |
 |
ICON Public Limited Company
ICLR
|
2.72 B | $ 103.21 | 1.02 % | $ 8.51 B |  Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 263.43 | -0.12 % | $ 21.9 B | USA |
 |
Neogen Corporation
NEOG
|
-536 M | $ 9.45 | -0.94 % | $ 2.05 B | USA |
 |
Celcuity
CELC
|
-449 M | $ 125.68 | 3.84 % | $ 5.88 B | USA |
 |
NeoGenomics
NEO
|
-434 M | $ 8.61 | 3.86 % | $ 1.1 B | USA |
 |
National Research Corporation
NRC
|
-17.3 M | $ 17.11 | -0.7 % | $ 383 M | USA |
 |
Myriad Genetics
MYGN
|
-1.12 B | $ 4.83 | 1.05 % | $ 447 M | USA |
 |
Natera
NTRA
|
-1.94 B | $ 204.39 | 0.31 % | $ 20.1 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
9.99 B | $ 196.63 | 0.21 % | $ 21.8 B | USA |
 |
Invitae Corporation
NVTA
|
-4.83 B | - | - | $ 21.2 M | USA |
 |
OpGen
OPGN
|
-294 M | - | -16.95 % | $ 1.54 M | USA |
 |
PerkinElmer
PKI
|
6.05 B | - | -0.91 % | $ 14.7 B | USA |
 |
Organovo Holdings
ONVO
|
-342 M | - | -2.3 % | $ 19.4 M | USA |
 |
Precipio
PRPO
|
-103 M | - | - | $ 49.3 M | USA |
 |
Personalis
PSNL
|
-550 M | $ 5.96 | -2.3 % | $ 353 M | USA |
 |
Senseonics Holdings
SENS
|
-1.02 B | $ 7.27 | 3.12 % | $ 303 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
-2.23 B | $ 19.06 | -7.88 % | $ 205 M | China |